Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing quality in post-acute cardiovascular and stroke care: Why national leadership and certification matter.

The American journal of medicine·2026
Same author

Post-acute cardiovascular and stroke care and the potential of certification programs: A 'Call to Action'.

The American journal of medicine·2026
Same author

Protein phosphatase 2A subunit B55 alpha is required for angiotensin type 2 receptor elicited natriuresis.

American journal of physiology. Renal physiology·2025
Same author

Catecholamine-induced hypertensive crises: current insights and management.

The lancet. Diabetes & endocrinology·2023
Same author

Decoding Angiotensin Receptors: TOMAHAQ-Based Detection and Quantification of Angiotensin Type-1 and Type-2 Receptors.

Journal of the American Heart Association·2023
Same author

Association of cancer with the risk of developing hypertension.

European heart journal. Quality of care & clinical outcomes·2023

Related Experiment Video

Updated: Jun 13, 2026

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Aldosterone and cardiovascular disease.

Robert M Carey1

  • 1Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia 22908-1414, USA. rmc4c@virginia.edu

Current Opinion in Endocrinology, Diabetes, and Obesity
|April 29, 2010
PubMed
Summary

Recent research highlights the renin-angiotensin-aldosterone system

Area of Science:

  • Endocrinology and cardiovascular science
  • Renal physiology and pathophysiology

Background:

  • The renin-angiotensin-aldosterone system (RAAS) is crucial for blood pressure and fluid balance.
  • Elevated aldosterone contributes to cardiovascular and renal damage, including inflammation and fibrosis.
  • Recent findings reveal new insights into aldosterone's role in target organ damage.

Purpose of the Study:

  • To review recent advances in understanding aldosterone's role in cardiovascular and renal disease.
  • To explore novel mechanisms of aldosterone secretion and its tissue-damaging effects.
  • To discuss new findings on the genetic control of aldosterone and its clinical implications.

Main Methods:

  • Review of recent scientific literature on aldosterone and cardiovascular/renal disease.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Related Experiment Videos

Last Updated: Jun 13, 2026

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

  • Analysis of novel findings on genetic control of aldosterone secretion.
  • Examination of mechanisms of aldosterone-induced tissue damage.

    • Main Results:

    • Circadian clock genes may regulate aldosterone secretion; their disruption is linked to hypertension.
    • First animal models for idiopathic hyperaldosteronism have been developed.
    • Glucocorticoids can activate cardiac mineralocorticoid receptors in cardiovascular disease.
    • Interactions between mineralocorticoid and angiotensin AT1 receptors exacerbate target organ damage.
    • Endogenous cardiotonic steroids may contribute to sodium-loading-induced tissue damage.

    Conclusions:

    • New understanding of aldosterone's impact on cardiovascular disease opens research avenues.
    • Recent discoveries offer potential for future therapeutic strategies targeting aldosterone pathways.
    • Further research is warranted to translate these findings into clinical practice.